Effects of Exercise on Long-Range Autocorrelations in Parkinson's Disease

Locomotion of Parkinsonian Patient: Are There Relations Between the Long Range Autocorrelations and the Neurological Impairments, Walking Abilities and the Practice of Physical Exercise?

Parkinson's disease (PD) is one of the most common neurodegenerative disorders. The parkinsonian gait is characterized by reducted stride length and gait speed, postural disorders (with a high risk of falling) and a modification of stride duration variability. This variability can be assessed by its magnitude (SD and CV) and its temporal organization (long-range autocorrelations). Healthy human gait presents with an interdependency between consecutive cycles that can span over hundreds of strides (long-range autocorrelations). Numerous observations plead for a relation between long-range autocorrelations and functional abilities of the system. Complementary to drugs, rehabilitation becomes an important way to treat PD.

The aim of our study is to assess by a controlled, randomized, single blinded clinical study, the effect of physical exercise on stride duration variability, neurological impairments and walking abilities of parkinsonian patients.

Physical exercise program will include 30 sessions spread over 15 weeks following the guidelines. Long-range correlations analysis, including the study of Hurst and α exponents, will be performed on a minimum of 512 consecutive cycles. Finally, the functional assessment of the parkinsonian patient will be done according to International Classification of Functioning Disability and Health (ICF).

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

BACKGROUND

One of the most common features of human movement is its variability across multiple repetition of the same rhythmic task (1). In humans, many periodic signals, such as gait, heartbeat, respiratory and neuronal activities are characterized by their temporal complexity, fluctuating in a complex manner over time. Although fluctuations between cycles could appear to vary randomly, without apparent correlations between cycles, healthy systems possess the memory of preceding values of the series displaying a complex temporal structure.

In order to assess variability in physiological time series, several mathematical methods can be used. On one hand, classical mathematical methods, usually applied on shorter time series (tens of data points), quantify the fluctuation magnitude in a set of values independently of their order in the distribution, by computing the standard deviation (SD) and the coefficient of variation (CV). On the other hand, more complex mathematical methods, applied on longer time series (≥512 cycles), can be used to assess the fluctuation dynamics over time (3). These latter methods have demonstrated that variability of numerous physiological signals (cardiac and respiratory rhythm or locomotor activities e.g.) exhibit long-range autocorrelations, whereby the statistical inter-dependency between cycles spans of a very large number of cycles (14).

This temporal organization of variability is thus an intrinsic property within numerous biological systems. Moreover, it could provide insight into the neurophysiological organization and into the regulation of these systems (32). Recent studies claimed that these fluctuations, included in an optimal range, would represent the underlying physiologic capability to make flexible adaptations to everyday stresses placed on the human body (32). Therefore, the presence of such temporal dynamics is thought to be a critical marker of health and their breakdown as an index of pathological condition (18, 25, 32). In human heart rate for instance, deviations from an optimum of variability in either the direction of randomness (atrial fibrillation e.g.) or the over-regularity (congestive heart failure e.g.) indicate the loss of the adaptive capabilities of the system (9, 32).

Alongside, some central nervous system diseases influence the variability, especially, of gait. Indeed, neurodegenerative disorders such as Parkinson and Huntington diseases are characterized, among others, by a modification of walking variability (observed by a breakdown of long-range autocorrelations) and a high risk of falling. Although the origin of long-range autocorrelation remains unknown, their breakdown in such diseases suggests a central control mechanism (8, 11, 13, 16, 17, 36).

RESEARCH PROJECT

Affecting about 1% of the population over the age of 60, Parkinson's disease (PD) is one of the most common neurodegenerative disorders. PD is progressive in nature, and so patients face increased difficulties with activities of daily living and various aspects of mobility such as gait, transfers, balance, and posture. Ultimately, this leads to decreased independence, inactivity, and social isolation, resulting in reduced quality of life. Consequently, the improvement of locomotion is one of the most important aims of the management of PD.

The management of PD has traditionally centered on drug therapy, with levodopa viewed as the "gold standard" treatment. However, even with optimal medical management, parkinsonian patients experience deterioration in body function, daily activities and participation. For this reason, support has been increasing for the inclusion of rehabilitation therapies as an adjuvant to pharmacological and neurosurgical treatment. Indeed, regular physical activity slows down the progression and decrease the fall risk. Moreover, exercise has demonstrated its effectiveness for both preservation of functional abilities and prevention of complications (cardiovascular, osteoporosis,…).

Until now, few studies have included the analysis of variability in the functional assessment of patients presenting a neurological disease, such as PD. Yet, walking disorders and falls represent not only an important cost for the society but also a sizeable individual risk of morbi/mortality. An appropriate rehabilitation program should allow for reduction at once the risks and costs resulting from these disorders. The investigator hypothesize that the analysis of walking variability could be useful as clinical tool in the assessment of fall risk and as assessment tool of the therapeutic effectiveness (medication and/or physical exercise) in PD. Therefore, the aims of this study are (1) to assess the influence of physical exercise on human walking variability and (2) to study its potential correlations with walking abilities and neurological impairments of parkinsonian patients.

Patients

The investigators will recruit 50 patients with idiopathic Parkinson's disease from the department of Neurology of Cliniques universitaires Saint-Luc (Brussels, Belgium) The study is approved by the ethics committee. All patients will give informed written consent to the study. Eligibility criteria are: diagnosis idiopathic Parkinson (according to the Brain Bank criteria of the United Kingdom Parkinson's Disease Society), disease severity (according to modified Hoehn & Yahr stages I to IV), absence of dementia (Minimal Mini Mental State Examination score of 24 or higher), stable drug usage in the last 4 weeks and adequate vision and hearing, achieved using corrective lenses and/or hearing aid if required. Patients will be excluded if they have severe co-morbidity, other neurological problems, acute medical problems (e.g. MI, diabetes) and joint problems affecting mobility, and unpredictable "Off"-periods (score >2, MDS-UPDRS item 4.5).

Procedure

The present study is a controlled, randomized, single blinded clinical study with a crossover design. The control group will not change its usual physical activity whereas the intervention group will benefit from the physical exercise program. This latter will include 30 sessions of circuit-group training of 60 min (twice a week) spread over 15 weeks. Then, the two groups will be crossed. According to the recent guidelines, the program will include a specific work on balance, posture, gait, fitness, dual tasks and stretching. All sessions will be performed at an adequate intensity (i.e. 60-80% of predicted maximal heart rate). At least 512 cycles will be recorded (at a high sampling rate (512 Hz)) on a treadmill at a self-selected comfortable speed using a unidimensional accelerometer taped on the right lateral malleolus.

Functional assessment based on the 3 domains of the International Classification of Functioning, Disability and Health (ICF)

Patients will be assessed before intervention (T0) and at 15 (T1), 30 (T2), 45 (T3) and 60 weeks (T4) among the 3 ICF domains:

Impairments will assessed by MDS-UPDRS, an instrumented gait analysis (kinematic, kinetic, electromyographic and energetic) (18), the 6 minute walk distance, the 10 meter walk test, the ABC-Scale and the BESTest (including the Functional Reach Test, the Push & Release and the Get Up & Go test).

Activities, participation and quality of life will be evaluated the Impact on Participation and Autonomy Questionnaire (IPAQ) and a fall diary.

Walking variability analysis

Revolution time variability will be appreciated by classical and complex mathematical methods. Classical mathematical methods (standard deviation, coefficient of variation) allow for evaluating the fluctuation magnitude, while complex mathematical methods (long-range autocorrelations) assess the dynamics of fluctuations over time (3).

The presence of long-range autocorrelations will be evaluated using the integrated approach proposed by Rangarajan and Ding and validated by Crevecoeur et al. in the context of physiological time series. These methods are described in greater details elsewhere. Briefly, the Hurst exponent (H) will be calculated using the rescaled range analysis and the α exponent will be evaluated using the power spectral density of the time series. For each time series, both methods will be applied to sequences of 512 consecutive gait strides.

In theory, the exponents H and α are asymptotically related by the relation H. Hence, the integrated approach consists of separately computing H and α, and verifying that these two parameters are consistent through the equation d=H-(1+α)/2=0. A value of d ≤ 0.10 is considered acceptable since the asymptotic parameters are evaluated on finite time series.

In summary, the following three conditions must be satisfied to conclude for the presence of long-range autocorrelations :

H > 0.5; α is significantly different from 0 and lower than 1; and d ≤ 0.10

When inconsistencies appear between H and α, the investigators will use the randomly shuffled surrogate data test to reject the null hypothesis that the series under investigation has no temporal structure (i.e. uncorrelated random process).

PERSPECTIVES

By studying the influence of physical exercise on human walking variability and its potential correlations with walking abilities and neurological impairments of parkinsonian patients, the investigators hope to demonstrate that the analysis of walking variability could be use as a clinical tool in the assessment of fall risk and as an assessment tool of the therapeutic effectiveness (medication and/or physical exercise) in PD.

Study Type

Interventional

Enrollment (Anticipated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Brussels
      • Woluwé-Saint-Lambert, Brussels, Belgium, 1200
        • Recruiting
        • Université catholique de Louvain - Cliniques universitaires Saint-Luc
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Diagnosis idiopathic Parkinson according to the Brain Bank criteria of the United Kingdom Parkinson's Disease Society
  • Disease severity according to modified Hoehn & Yahr stages I to IV
  • Absence of dementia Minimal Mini Mental State Examination score of 24 or higher
  • Stable drug usage in the last 4 weeks
  • Adequate vision and hearing, achieved using corrective lenses and/or hearing aid if required

Exclusion Criteria:

  • Severe co-morbidity, other neurological problems, acute medical problems (e.g. MI, diabetes) and joint problems affecting mobility
  • Unpredictable "Off"-periods (score >2, MDS-UPDRS item 4.5)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Physical Exercise
All patients will receive a circuit-group training including a specific work of balance, posture, gait, fitness, dual tasks and stretching.
The physical exercise program will include 30 sessions of 60 minutes (twice a week). According to the recent guidelines, the program will include a specific work on balance, posture, gait, fitness, dual tasks and stretching.
No Intervention: Control
All patients will not change their physical activities

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Balance Evaluation Systems Test (BESTest)
Time Frame: Change from baseline in balance measures at an expected average of 15 (T1), 30 (T2), 45 (T3) and 60 weeks (T4)
Change from baseline in balance measures at an expected average of 15 (T1), 30 (T2), 45 (T3) and 60 weeks (T4)

Secondary Outcome Measures

Outcome Measure
Time Frame
Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS)
Time Frame: Change from baseline in MDS-UPDRS at an expected average of 15 (T1), 30 (T2), 45 (T3) and 60 weeks (T4)
Change from baseline in MDS-UPDRS at an expected average of 15 (T1), 30 (T2), 45 (T3) and 60 weeks (T4)
Six Minute Walk Distance (6-MWD)
Time Frame: Change from baseline in exercise tolerance at an expected average of 15 (T1), 30 (T2), 45 (T3) and 60 weeks (T4)
Change from baseline in exercise tolerance at an expected average of 15 (T1), 30 (T2), 45 (T3) and 60 weeks (T4)
10 Meter Walk Test (10-MWT)
Time Frame: Change from baseline in walking speed, step lenght and cadence at an expected average of 15 (T1), 30 (T2), 45 (T3) and 60 weeks (T4)
Change from baseline in walking speed, step lenght and cadence at an expected average of 15 (T1), 30 (T2), 45 (T3) and 60 weeks (T4)
Long-range autocorrelations
Time Frame: Change from baseline in long-range autocorrelations at an expected average of 15 (T1), 30 (T2), 45 (T3) and 60 weeks (T4)
Change from baseline in long-range autocorrelations at an expected average of 15 (T1), 30 (T2), 45 (T3) and 60 weeks (T4)
Instrumented gait analysis
Time Frame: Change from baseline in gait parameters (kinematic, kinetic, electromyographic and energetic) at an expected average of 15 (T1), 30 (T2), 45 (T3) and 60 weeks (T4)
Change from baseline in gait parameters (kinematic, kinetic, electromyographic and energetic) at an expected average of 15 (T1), 30 (T2), 45 (T3) and 60 weeks (T4)
Impact on Participation and Autonomy Questionnaire (IPAQ)
Time Frame: Change from baseline in participation and quality of life at an expected average of 15 (T1), 30 (T2), 45 (T3) and 60 weeks (T4)
Change from baseline in participation and quality of life at an expected average of 15 (T1), 30 (T2), 45 (T3) and 60 weeks (T4)
Activities-specific Balance Confidence Scale (ABC-Scale)
Time Frame: Change from baseline in subjective balance measures (fear of falling) at an expected average of 15 (T1), 30 (T2), 45 (T3) and 60 weeks (T4)
Change from baseline in subjective balance measures (fear of falling) at an expected average of 15 (T1), 30 (T2), 45 (T3) and 60 weeks (T4)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Thibault B. Warlop, Doctor, Université Catholique de Louvain

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2014

Primary Completion (Anticipated)

May 1, 2016

Study Registration Dates

First Submitted

April 14, 2015

First Submitted That Met QC Criteria

April 16, 2015

First Posted (Estimate)

April 17, 2015

Study Record Updates

Last Update Posted (Estimate)

January 28, 2016

Last Update Submitted That Met QC Criteria

January 27, 2016

Last Verified

January 1, 2016

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Parkinson's Disease

Clinical Trials on Physical Exercise

Subscribe